Truncated Superstolide A Analogues for Scalable Anticancer Synthesis
Solution Overview
Problem
The scarcity of superstolides A and B, potent marine macrolides with anticancer activity, limits further biological investigation due to challenging isolation and environmental concerns, necessitating the development of novel compounds with similar pharmacologic properties for commercial-scale production and therapeutic use.
Innovation Solution
The synthesis of truncated superstolide A analogues, which maintain the 16-membered macrolactone pharmacophore but simplify the functionalized cis-decalin to a cyclohexene ring, allowing for efficient enantioselective synthesis and potential as anticancer agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If superstolides A and B are isolated from the marine sponge Neosiphonia superstes, then potent anticancer activity is obtained, but the isolation yield is extremely low (0.003% and 0.0003% respectively) and the process is difficult and dangerous
Solution Approach 1:
The patent creates simplified analogues (compounds of formula I) that copy the essential pharmacophore features of superstolides A and B - specifically the 16-membered macrolactone ring system - while replacing the complex functionalized cis-decalin moiety with a simpler cyclohexene ring. This copying approach allows retention of anticancer activity while enabling scalable synthesis.
Solution Approach 2:
The patent replaces the expensive, scarce natural product (superstolides obtained at 0.003% and 0.0003% yield) with synthetic analogues that can be produced more economically and in larger quantities through chemical synthesis, making the therapeutic agent accessible for commercial use.
2Quantity of substance
If large amounts of marine sponge Neosiphonia superstes are collected to obtain sufficient superstolides for biological investigation, then enough material is obtained for study, but significant damage is caused to the marine habitat
Solution Approach 1:
Instead of harvesting large quantities of the rare marine sponge to obtain sufficient superstolide for biological investigation, the patent synthesizes analogue compounds that replicate the essential pharmacological features, thereby obtaining unlimited quantities without further marine exploitation.
Solution Approach 2:
The patent segments the superstolide molecule into its essential pharmacophore (the 16-membered macrolactone) and non-essential portions (the complex functionalized cis-decalin), retaining only the critical features needed for biological activity while discarding the parts that complicate production and sourcing.
3Reliability
If the complex molecular structure of superstolides is maintained, then the original pharmacologic properties are preserved, but the synthesis becomes extremely difficult and time-consuming
Solution Approach 1:
The patent segments the superstolide molecule into the essential 16-membered macrolactone pharmacophore and the optional cyclohexene ring, separating the critical functional elements from the complex substituted decalin system. This segmentation retains pharmacologic activity while dramatically simplifying the molecular structure for synthesis.
Solution Approach 2:
The patent extracts and removes the complex functionalized cis-decalin moiety from the superstolide structure, retaining only the essential macrolactone core and a simplified cyclohexene ring. This extraction eliminates synthetic complexity while preserving the key pharmacological features responsible for anticancer activity.
Data Source
AI summary
The invention provides compounds useful as anti-cancer agents.